Department of Cardiac Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
CAS Key Laboratory of Soft Matter Chemistry, Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, China.
Biomater Adv. 2022 Jun;137:212836. doi: 10.1016/j.bioadv.2022.212836. Epub 2022 May 2.
Following vein grafting, the vein must adapt to arterial hemodynamics, which can lead to intimal hyperplasia (IH) and restenosis. Moreover, endothelial-to-mesenchymal transition (EndMT) components are highly associated with IH. Therefore, in this study, we aimed to design an extravascular film loaded with rapamycin (extravascular rapamycin film [ERF]) to limit vein graft stenosis. The film exhibited stable physicochemical properties as well as in vivo and in vitro biocompatibility. In vivo, the film inhibited the EndMT by activating the autophagy pathway. Moreover, rapamycin enhanced this biological effect. Collectively, these findings highlighted the applicability of ERF as a new therapeutic target for preventing vein graft restenosis.
静脉移植后,静脉必须适应动脉血流动力学,这可能导致内膜增生(IH)和再狭窄。此外,内皮到间充质转化(EndMT)成分与 IH 高度相关。因此,在这项研究中,我们旨在设计一种负载雷帕霉素的血管外膜(血管外雷帕霉素膜[ERF])来限制静脉移植物狭窄。该膜表现出稳定的物理化学性质以及体内和体外的生物相容性。在体内,该膜通过激活自噬途径抑制 EndMT。此外,雷帕霉素增强了这种生物学效应。总之,这些发现强调了 ERF 作为预防静脉移植物再狭窄的新治疗靶点的适用性。